Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
ERCC1	2067	FLUOROURACIL	CHEMBL185		PharmGKB, NCI	9268987
ERCC1	2067	PHENYLTHIOUREA	CHEMBL263376		PharmGKB
ERCC1	2067	THALIDOMIDE	CHEMBL468		PharmGKB
ERCC1	2067	CYCLOSPORINE	CHEMBL160		NCI	9933022
ERCC1	2067	HERBIMYCIN	CHEMBL479533		NCI	9933022
ERCC1	2067	OXALIPLATIN	CHEMBL414804		PharmGKB

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ERCC1	rs11615	A	carboplatin	efficacy	no		Allele A is not associated with response to carboplatin and pemetrexed in people with Mesothelioma as compared to allele G.	21262916	827699103
ERCC1	rs2298881	A	fluorouracil	efficacy	yes	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. In multivariate analysis the number of risk alleles was significantly associated with survival (1-3 alleles HR 1.66 (95% CI 1.06-2.59) 3-6 alleles HR 2.28 (95% CI 1.28-4.03) P-value for trend = 0.001). Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele A is associated with increased response to fluorouracil, Platinum compounds or radiotherapy in people with Stomach Neoplasms as compared to allele C.	28796378	1448926344
ERCC1	rs11615	AA	Platinum compounds	efficacy	yes	Please note; specific p-value for this significant association not given, but a 5% probability level was considered significant. [stat_test: logistic regression]	Genotype AA is associated with decreased response to Platinum compounds in women with Ovarian Neoplasms as compared to genotype GG.	22329723	827922697
ERCC1	rs11615	GG	fluorouracil	efficacy	yes	Response was determined by survival rates.	Genotype GG is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	21057378	1449754461
ERCC1	rs3212986	C	Platinum compounds	efficacy	no	No significant relationship between genotype and drug response was detected.	Allele C is not associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	22761669	982046448
ERCC1	rs11615	G	Platinum compounds	efficacy	no	No significant relationship between genotype and drug response was detected.	Allele G is not associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	22761669	982046427
ERCC1	rs11615	AG + GG	capecitabine	efficacy	yes	p-value and OR below for multivariate analysis. In univariate analysis, 30.6% of those with the AA genotype achieved pathological complete response, compared with 16.2% of those with the AG genotype and 0% of those with the GG genotype. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AG + GG is associated with decreased response to capecitabine and radiotherapy in people with Rectal Neoplasms as compared to genotype AA.	25026457	1444934692
ERCC1	rs11615	AA + AG	Platinum compounds	efficacy	yes	Platinum-based doublets consisting of cisplatin or carboplatin plus gemcitabine, vinorelbine, taxane or pemetrexed. Response defined as complete or partial response; non-response defined as stable disease or progression disease. Significant results were also seen within a group of patients with squamous cell carcinoma subtype. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AA + AG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	25069034	1296667129
ERCC1	rs3212986	CC	bevacizumab	efficacy	no	No significant association with response, progression-free survival or overall survival was found for this variant.	Genotype CC are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AA + AC.	27995989	1448568298
ERCC1	rs3212986	A	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele C.	28796378	1448926460
ERCC1	rs11615	A	Platinum compounds	efficacy	no	Patients were treated with cisplatin or carboplatin in combination with a third-generation drug (gemcitabine, paclitaxel, pemetrexed or vinorelbine). No significant association with overall response rate (ORR), overall survival (OS) or progression-free survival (PFS) was found for this SNP. Please note that alleles have been complemented to the plus chromosomal strand.	Allele A is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	29662106	1449752387
ERCC1	rs3212986	CC	Platinum compounds	efficacy	yes	Patients were treated with cisplatin or carboplatin in combination with a third-generation drug (gemcitabine, paclitaxel, pemetrexed or vinorelbine). Patients with the CC genotype had better overall response rates as compared to those with the AA and AC genotypes. The authors also found that in patients with EGFR mutations, the CC genotype was associated increased progression-free survival times as compared to the AA and AC genotypes. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	29662106	1449752300
ERCC1	rs11615	A	granisetron	efficacy	no	Patients with cancer, treated with cisplatin who had been treated with granisetron and palonsetron. Nausea and vomiting episodes were recorded for the first 120 h post cisplatin. With regard to vomiting events, presence/absence of symptoms and the time of onset were described. Nausea severity was categorized using a 4-point Likert scale (0 = no nausea, 1 = mild nausea, 2 = moderate nausea and 3 = severe nausea) according to the subjective assessment of each patient.	Allele A is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to allele G.	29177570	1449170208
ERCC1	rs11615	AA	cisplatin	efficacy	yes	This SNP was presented as ERCC1 C/T at codon 118. Patients the T allele were significantly less likely to have disease progression as compared to patients homozygous for the C allele. No other association between outcome (time to progression or overall survival) and genotype was found for this SNP.	Genotype AA is associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	18347182	1183700726
ERCC1	rs11615	A	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.	28796378	1448926466
ERCC1	rs3212948	C	fluorouracil	efficacy	yes	NB: Improved overall response rate is reported as for the G allele, gene is on the negative strand so given here as the C allele.	Allele C is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.	20385995	769261461
ERCC1	rs3212986	A	Platinum compounds	efficacy	yes	Please note; 5% probability level was considered significant. [stat_test: logistic regression]	Allele A is not associated with decreased response to Platinum compounds in women with Ovarian Neoplasms as compared to allele C.	22329723	827922747
ERCC1	rs11615	GG	bevacizumab	efficacy	yes	Patients with the GG genotype had decreased overall survival in multivariable analysis. However, note that this was only a "nominally" significant association: formally significant was defined as p<0.0026, and nominally significant as p<0.05. No association with progression-free survival or response was found. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AA + AG.	27995989	1448568304
ERCC1	rs11615	GG	fluorouracil	efficacy	no	Patients were taking either IFL (irinotecan + fluorouracil + leucovorin; n=114), FOLFOX (fluorouracil + oxaliplatin + leucovorin; n=299) or IROX (irinotecan + oxaliplatin; n=107). No significant association was seen between this variant and confirmed response rate, overall survival or time to progression in any of the treatment groups OR all treatment groups considered together. Significance level was set at 0.01. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	20530282	1448522397
ERCC1	rs3212986	AC + CC	granisetron	efficacy	yes	Patients with cancer, treated with cisplatin who had been treated with granisetron and palonsetron. Nausea and vomiting episodes were recorded for the first 120 h post cisplatin. With regard to vomiting events, presence/absence of symptoms and the time of onset were described. Nausea severity was categorized using a 4-point Likert scale (0 = no nausea, 1 = mild nausea, 2 = moderate nausea and 3 = severe nausea) according to the subjective assessment of each patient.	Genotypes AC + CC are associated with increased response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotype AA.	29177570	1449170340